News items related to:
-
The right to health is compulsory: Time for action on dolutegravir – now!
Why Algeria, Azerbaijan, Belarus, Brazil, Bulgaria, China, Colombia, Kazakhstan, Mexico, Romania, Russia, and Turkey must issue compulsory licences on dolutegravir...
-
Still an avoidable tragedy: Brazil’s view on the EU-Mercosur free-trade agreement
The signing of the Free Trade Agreement (FTA) between Mercosur and the European Union on 28 June 2019, means that...
-
Old wine in new bottles: Keep TRIPS-plus provisions out of the RCEP FTA!
Intellectual property barriers, which would hinder access to affordable medicines, have supposedly been removed from the draft RCEP free-trade agreement...
-
Ukraine hosts regional congress on intellectual property and access to medicines
Over 100 people from more than 10 countries met in Kiev for the ‘Congress on Intellectual Property (IP) and Access...
-
Drug users under the microscope: Temo’s experience in Georgia
“I was in prison when I was diagnosed with Hepatitis B,” says Temo, 33. “I was just left with the...
-
Ukraine: First civil society organization to oppose Merck’s patent application ( MK-8591) on the grounds of “obviousness”
On 28 May 2019, 100 Percent Life (the Network) submitted an opposition to the Ukrainian Patent and Trademark Office against...
-
Politics of Death: The End of Brazil’s Department of AIDS
Adapted from a post published by ABIA, Global AIDS Policy Watch: A joint story from Brazilian NGOs that have denounced...
-
Pipeline patents – Brazilian Supreme Court decides on the present and the future
On Wednesday 22 May, the largest trial in the history of the Brazilian Federal Supreme Court (STF) involving the pharmaceutical...
-
Truvada for PrEP. Gilead grilled at US congressional hearing
The USA is being charged $70 per pill for a drug, yet tax payers largely funded the research. Thanks to...
-
What’s wrong with IP rights? Protecting medicines from competition can be costly
Gram for gram a HIV medicine costs more than gold. What makes drugs so costly? Is it research and development?...
-
Activists file post-grant opposition challenging a patent preventing purchase of cheaper treatment for hepatitis C
GTPI has presented an argument to the Brazilian Patent Office (INPI) to invalidate the patent granted for the drug daclatasvir....
-
Kularb’s story: Optimal treatment would reduce HIV-related stigma
Interview by Gemma Taylor. “I was told I’d have to wait for 10 more people to die before I could...